Trial
NCT03507374
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
Regeneron Pharmaceuticals
Condition
Stroke
Intervention
Alirocumab
Why stopped
Funding withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-21